June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluating the efficacy of treatment with an LXR agonist on the pathogenesis of early AMD
Author Affiliations & Notes
  • Faryan Tayyari
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Mayur Choudhary
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Peter Tontonoz
    Pathology, UCLA, Los Angeles, California, United States
  • James T Handa
    Ophthalmology, Wilmer Eye Institute, Johns Hopkins, Baltimore, Maryland, United States
  • Goldis Malek
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Faryan Tayyari, None; Mayur Choudhary, None; Peter Tontonoz, None; James Handa, None; Goldis Malek, None
  • Footnotes
    Support  The Edward N. & Della L. Thome Memorial Foundation AMD research Award (GM), NIH Grant EY02868(GM), P30EY005722 (Duke Eye Center) and RPB Core Grant (Duke Eye Center)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1940. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Faryan Tayyari, Mayur Choudhary, Peter Tontonoz, James T Handa, Goldis Malek; Evaluating the efficacy of treatment with an LXR agonist on the pathogenesis of early AMD. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1940.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previously, we demonstrated that the Liver X Receptor (LXR) can regulate lipid metabolism and inflammation in the eye, similar to its reported functions in other endocrine organs. We found that aged LXR knockout mice develop several phenotypic features of dry AMD. Herein, we tested the therapeutic potential of LXR activation on removal of accumulated lipids in Bruch’s membrane and inflammatory cells within the retina, using the apoB100 transgenic mouse model.

Methods : Expression lipid metabolism (i.e. ABCA1, SREBP, apoE, FAS) and inflammatory (i.e. IL-6, IL-18, NF-kB, CFH, MCP-1, TGF-b, OPN, CD36) were investigated in human primary RPE (hRPE) cell lines (n=3 replicates) treated with LXR agonists (GW3965, TO901317), and an antagonist (GSK1440233A). ApoB100 mice, characterized by the accumulation of lipids within Bruch’s membrane (2 months of age; n=4-6, males and females) were fed either a low fat diet (LFD) or LFD enriched with an LXR agonist for 5 months. Wild-type (WT) and apoB100 mice on normal chow served as additional controls. Visual function and in vivo morphology were examined by electroretinography (ERG) and optical coherence tomography (OCT), respectively. Electron and light microscopy were used to quantify morphological changes (n=3 mice).

Results : LXR activation in hRPE cells upregulated expression of lipid regulatory genes (SREBP, FAS, apoE) and repressed the expression of inflammatory genes (IL-6, NF-kB, TGF-b, OPN). Scotopic a-wave amplitudes decreased in apoB100 mice on normal diet compared to WT mice, which improved in mice on the LFD. No differences in ERG amplitudes were seen due to treatment with the LXR agonist. OCT, electron and light microscopy revealed a decrease in retinal pathology in apoB100 mice treated with the LXR agonist, including the presence of focal RPE degeneration and sub-RPE deposits. Finally, an increase in Iba+ and F4/80+ cells and GFAP immunoreactivity was seen in the retina of apoB100 mice compared to WT. Treatment with the LXR agonist resulted in a decrease in the number of retinal inflammatory cells, extent of GFAP staining, and apolipoprotein E accumulation in Bruch’s membrane in apoB100 mice.

Conclusions : The data support the hypothesis that LXR is an AMD regulatory signaling pathway and that its activation may be therapeutically beneficial in ameliorating pathologies associated with the disease.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×